The Trump administration has launched an investigation into Germany’s drug pricing practices, citing concerns that the country is not paying its fair share for American-made medicines. U.S. Trade Representative Jamieson Greer announced the move, which is aimed at determining whether Germany’s practices are unfair to U.S. pharmaceutical companies.
Unfair Pricing Practices
Germany has been accused of forcing pharmaceutical companies to sell their drugs at steep discounts, making the medicines artificially cheap. This practice, known as ‘persistent underpayment for innovative pharmaceutical products,’ has been criticized for shifting high costs to Americans. For the most expensive drugs, Americans already pay four times more than Germans.
The investigation will last into the fall, with a public hearing on September 22. If the Trump administration concludes that Germany has acted unfairly, it could slap tariffs on Germany in response. The move is seen as part of the Trump administration’s efforts to make drugs more affordable for Americans.
A Fair Deal for Americans
The Trump administration has been pushing for fair trade practices with European countries, including Germany. The president has threatened tariffs on several occasions to get European leaders to agree to better trade deals. In this case, the goal is to get Germany to pay more for American-made drugs, which would help reduce the cost of medicines for Americans.
Other countries, such as the United Kingdom, have already agreed to pay more for American medicines after facing similar pressure from the Trump administration. The U.K. agreed to a deal earlier this year that shifts some of the unfair burden off Americans.
The Trump administration’s efforts to hold Germany accountable for its drug pricing practices have been praised by some as a necessary step to protect U.S. pharmaceutical companies and make drugs more affordable for Americans.
Original reporting: Fox News (HLL/CB) — read the source article.
